Skip to main content
Skip to navigation
PR News
Expand Search
Menu
Access
myPennMedicine
Home
Publications and Special Projects
The Research Legacy of Penn Medicine
The Aging Brain
Drug Discovery
Drug Discovery
Research led by
Kurt Brunden, PhD
, scientific director of the
Marian S. Ware Alzheimer and Benaroya Parkinson's Disease Drug Discovery Program, may have
resurrected a promising drug from therapeutic limbo
. The drug epothilone D (EpoD) was originally developed as an anti-cancer agent but didn't quite live up to its original promise. Investigators at the
Center for Neurodegenerative Disease Research
noted that EpoD was capable of readily crossing the blood-brain barrier, helping to stabilize critical cellular structures known as microtubules within nerve cells. In Alzheimer’s and other neurodegenerative diseases, tau tangles disrupt the railroad-track-like microtubules, leading to an impairment of nerve cell function and health. In a mouse model of Alzheimer’s disease, EpoD improved cognitive performance and prevented the formation of tau tangles in the brains of aging mice, with no side effects.
The research suggested the possibility that EpoD might have similar benefits for patients with AD and other neurodegenerative diseases
. Now, a drug company has
enrolled AD patients in clinical trials to test the drug
.
Share This Page:
Post
Tweet
Share
News Releases
News Blog
Publications & Special Projects
Internal Newsletters
Subscribe
Contact Us